Latest News and Press Releases

Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gengið frá samningi við DNB Carnegie Investment Bank AB (“DNB Carnegie”) um viðskiptavakt með bréf félagsins á Nasdaq markaðnum í...

REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding...

Viðskipti með hluti í Alvotech (NASDAQ: ALVO) hefjast í dag á Nasdaq markaðnum í Stokkhólmi. Félagið verður skráð undir auðkenninu „ALVO SDB“. Skráningu Alvotech í kauphöllina í Stokkhólmi er ætlað að...

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an...

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 7. maí nk. Uppgjörsfundur með greinendum, sem sendur er út í...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Vandœuvre-lès-Nancy, le 29 avril 2025 – 18 : 00 (CET) Communiqué de presse Pour diffusion immédiate Résultats Annuels 2024 de la Société PAT Premier résultat d'exploitation positif depuis la...

Er-Kim signs distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region

MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in...